Weak links: Advancing target-based drug discovery by identifying the most vulnerable targets.

Autor: Bosch B; Laboratory of Host-Pathogen Biology, The Rockefeller University, New York, New York, USA., DeJesus MA; Laboratory of Host-Pathogen Biology, The Rockefeller University, New York, New York, USA., Schnappinger D; Department of Microbiology and Immunology, Weill Cornell Medicine, New York, New York, USA., Rock JM; Laboratory of Host-Pathogen Biology, The Rockefeller University, New York, New York, USA.
Jazyk: angličtina
Zdroj: Annals of the New York Academy of Sciences [Ann N Y Acad Sci] 2024 May; Vol. 1535 (1), pp. 10-19. Date of Electronic Publication: 2024 Apr 10.
DOI: 10.1111/nyas.15139
Abstrakt: Mycobacterium tuberculosis remains the most common infectious killer worldwide despite decades of antitubercular drug development. Effectively controlling the tuberculosis (TB) pandemic will require innovation in drug discovery. In this review, we provide a brief overview of the two main approaches to discovering new TB drugs-phenotypic screens and target-based drug discovery-and outline some of the limitations of each method. We then explore recent advances in genetic tools that aim to overcome some of these limitations. In particular, we highlight a novel metric to prioritize essential targets, termed vulnerability. Stratifying targets based on their vulnerability presents new opportunities for future target-based drug discovery campaigns.
(© 2024 The Authors. Annals of the New York Academy of Sciences published by Wiley Periodicals LLC on behalf of The New York Academy of Sciences.)
Databáze: MEDLINE
Externí odkaz: